Live Breaking News & Updates on Sinai Health Network

Stay updated with breaking news from Sinai health network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioSpace Movers & Shakers, Dec. 18


Published: Dec 18, 2020
By Alex Keown
Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Kurtz held a number of leadership positions at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. ....

New York , United States , Rockefeller University , United Kingdom , Terri Gaskell , Peter Greenleaf , Scott Burger , Andrea Heslin Smiley , Eli Lilly , Jeffrey Vacira , Manny Triggiano , Dmitri Daveynis , Michael Weinblatt , N Manisha Shetty Gulati , Mervyn Turner , Sandip Kapadia , D Martin Carter , Djordje Filipovic , Perry Calias , Siemens Healthineers , Marylyn Rigby , Daphne Karydas , Badreddin Edris , David Enloe , Jeff Myers , Stanley Cohen ,

BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors


BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
NEW YORK, Dec. 17, 2020 BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia.
“We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, Founder and Chief Executive Officer of BeyondSpring. “In addition to his many years as an accomplished oncology ....

New York , United States , Jeffrey Vacirca , International Oncology Network , Oncology Network Development At Mt , Beyondspring The Company Or , Community Oncology Alliance , York Cancer Foundation , Sinai Health Network , Alan Huang , Chief Executive Officer , New York Cancer , Medical Director , Oncology Network Development , Sinai Health , American Red Cross , Greater New York , New York Cancer Foundation , Vice Chairman , Odonate Therapeutics , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , சர்வதேச புற்றுநோயியல் வலைப்பின்னல் , புற்றுநோயியல் வலைப்பின்னல் வளர்ச்சி இல் ம்த் , சமூக புற்றுநோயியல் கூட்டணி , யார்க் புற்றுநோய் அடித்தளம் ,